MC
NXTM

Moors & Cabot’s NxStage Medical Inc. NXTM Stock Holding History

Moors & Cabot’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-10,750
Closed -$137K – 553
2014
Q1 		$137K Buy
+10,750
New +$140K 0.03% 356

Other funds holding NXTM

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BA
Broadview Advisors Milwaukee, Wisconsin $324M AUM 0.76% 1-Year Est. Return

Moors & Cabot's NXTM Position: Q2 2014 in Review

Moors & Cabot sold out of NxStage Medical Inc. (NXTM) in Q2 2014, closing a stake of 10,750 shares — an estimated $137K sold.

Moors & Cabot first reported a position in NXTM in Q1 2014 and held it in 1 quarter. The position peaked at $137K in Q1 2014. 115 funds tracked by Wall St. Rank hold NXTM as of Q2 2014.

  • Moors & Cabot reported no remaining NxStage Medical Inc. position as of Q2 2014 after selling out during the quarter.
  • Moors & Cabot sold 10,750 NxStage Medical Inc. shares in Q2 2014, an estimated $137K.
  • Moors & Cabot first reported a position in NxStage Medical Inc. in Q1 2014 and held it in 1 quarter.
  • Moors & Cabot's NxStage Medical Inc. position peaked at $137K in Q1 2014.
  • 115 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q2 2014.

Based on Moors & Cabot's 13F filing for Q2 2014, filed 11 Aug 2014.